BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.

Waters Corporation is merging with BD’s Biosciences and Diagnostic Solutions business in a $17.5 billion deal to expand its capabilities in life sciences and diagnostics.

2025 年 7 月 14 日，美国马萨诸塞州，全球分析仪器领导者 Waters Corporation（纽约证券交易所代码：WAT）宣布，已与医疗技术巨头 Becton, Dickinson & ...

The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of ...

2025年7月14日，美国马萨诸塞州，全球分析仪器领导者Waters Corporation（纽约证券交易所代码：WAT）宣布，已与医疗技术巨头Becton, Dickinson & Company（BD，纽约证券交易所代码：BDX）达成最终协议，将整合BD旗下生物科学及诊断解决方案业务。此次交易通过反向莫里斯信托（Reverse Morris ...

Waters plans to combine with the Biosciences & Diagnostic Solutions business of BD (Becton, Dickinson & Co.), the companies said, in a $17.5 billion deal that would be the year’s largest within life ...

Waters Corporation (WAT) stock downgraded at Wells Fargo based on execution risks related to its $17.5B M&A deal with a unit of Becton Dickinson (BDX). Read more here;.

Kirkland & Ellis advises Waters on $17.5B merger with Becton Dickinson, creating a diagnostics and life sciences leader.

Waters Corporation announces a $17.5 billion acquisition of Becton Dickinson's bioscience unit, expanding its reach in ...

However, Waters has announced plans to merge with BD's life science and diagnostics segment in early 2026, which will dilute that interest in that highly regulated end market, going forward. The ...

Waters Corp.'s $17.5B merger with BD Biosciences aims to double revenue but raises risks. Read here for an investment ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.